Silo Pharma, Inc. (SILO) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Silo Pharma, Inc. is a developmental-stage biopharmaceutical and cryptocurrency company. Its biopharmaceutical focus includes developing therapeutics for PTSD, anxiety, fibromyalgia, Alzheimer's, and multiple sclerosis. In August 2025, the company adopted a cryptocurrency treasury strategy. On April 15, 2026 (subsequent to the period end), the company formed a subsidiary, Qwikagentsai Inc., to diversify into AI technology.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $18,026 | $18,026 |
| Net Loss | $(1,647,117) | $(1,031,437) |
| Loss Per Share (Basic/Diluted) | $(0.12) | $(0.23) |
| Cash and Cash Equivalents | $3,902,514 | $3,136,880 |
| Short-Term Investments | $2,129,659 | $2,314,550 |
| Working Capital | $6,098,849 | $6,737,542 |
| Crypto Assets (Fair Value) | $173,462 | $221,817 |
| Crypto Assets (Cost) | $68,673 | $98,584 |
Debt and Liquidity: The company reported no long-term debt. Total liabilities were $1,336,296, primarily consisting of deferred revenue ($703,553) and accounts payable ($632,743). Management believes current cash and short-term investments are sufficient to meet obligations for at least twelve months.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 59.7% to $1.65 million, driven by higher operating expenses and a swing in other income/expense from positive to negative.
- Operating Expenses: Total operating expenses rose 43.3% to $1.59 million. The primary driver was a 70.6% increase in Research and Development (R&D) expenses to $1.01 million. This included a non-cash charge of $714,000 for the acquisition of AI software assets (qwikagents.com) paid via stock issuance.
- Other Income/Expense: This line item swung from a $62,684 gain in Q1 2025 to a $52,457 loss in Q1 2026. The loss was caused by a $53,348 unrealized loss on crypto assets (fair value) and a $29,911 impairment loss on crypto assets (cost), offsetting interest income.
- Revenue: Revenue remained flat at $18,026, derived entirely from the amortization of deferred revenue related to a license agreement with Aikido Pharma Inc.
Guidance, Outlook, and Risks
Management Commentary: Management maintains that the company has sufficient liquidity to operate for the next 12 months. The company is advancing its lead product candidate, SPC-15 (intranasal treatment for PTSD), with an anticipated IND submission in 2026. The company continues to hold and stake digital assets (BTC, ETH, SOL) as part of its treasury strategy.
Risks and Contingencies:
- Crypto Volatility: Significant unrealized losses and impairments on crypto assets impacted the bottom line. The company holds assets at fair value and cost, subject to market fluctuations.
- Licensing Agreements: The Master License Agreement with the University of Maryland, Baltimore (UMB) was terminated in July 2025 and replaced with an option agreement expiring March 31, 2026. The company must exercise this option to retain rights to its SPU-16 program.
- Capital Needs: As a developmental-stage company with an accumulated deficit of $21.1 million, the company requires additional financing to fund clinical trials and operations.
Investor Verification Checklist
- License Option Status: Verify if the option to renew the UMB license for the SPU-16 program (expiring March 31, 2026) has been exercised or if a new agreement is in place.
- Crypto Asset Valuation: Review the specific holdings and fair value methodology for crypto assets, given the significant impairment and unrealized losses recorded in Q1 2026.
- AI Asset Utility: Assess the strategic value and development timeline of the "qwikagents.com" software acquired for $714,000 in stock, which was immediately expensed as R&D.
- Cash Burn Rate: Monitor the net cash used in operating activities ($822,623 for Q1) against current cash reserves to validate the 12-month liquidity runway.
- Stock Dilution: Note the issuance of 2.95 million shares in Q1 2026 (for services and asset acquisition), increasing outstanding shares from 13.3 million to 16.3 million.